Equities Analysts Offer Predictions for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Investment analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for Bolt Biotherapeutics in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($0.36) per share for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Other research analysts also recently issued research reports about the stock. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday. Stifel Nicolaus lowered their price target on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $1.13.

Bolt Biotherapeutics Stock Up 4.8 %

Shares of NASDAQ:BOLT opened at $0.44 on Thursday. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $16.84 million, a P/E ratio of -0.26 and a beta of 0.94. Bolt Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.56. The stock’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.56.

Institutional Investors Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC boosted its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth approximately $42,000. Millennium Management LLC purchased a new stake in Bolt Biotherapeutics in the fourth quarter valued at approximately $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics during the fourth quarter worth approximately $26,000. Finally, Velan Capital Investment Management LP purchased a new position in Bolt Biotherapeutics during the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.